Try as we might, we can’t cover all the biotech news out there! It’s summer, so the news is thinner on the ground than usual, but here’s a roundup of news that didn’t make the cut this week.

  • Swedish Hansa Medical is starting a long-term study to assess the success of kidney transplantation after treatment with its drug imlifidase, which is designed to minimise rejection in these patients.
  • The Italian company Menarini Ricerche has taken over sponsorship of a Phase I/II trial investigating a new treatment for acute myeloid leukemia, which was developed in collaboration with Polish biotech Selvita.
  • Britannia Pharmaceuticals reported good Phase III results for its add-on Parkinson’s disease treatment, which according to the UK company reduced symptoms of shaking in people with the disease.
  • Swedish Eurocine Vaccines came a step closer to the market with its nasal flu vaccine, which showed good safety results in older adults in a second Phase I/II trial.
  • Astellas Pharma bought Quethera to enhance the Japanese company’s ophthalmology pipeline with the UK biotech’s novel gene therapy candidate for glaucoma.
  • Rare disease specialist Therachon, based in Switzerland, has raised $60M (€52M) in mezzanine financing to help progress its treatment for achondroplasia and expand its rare disease pipeline.
  • A German-US research collaboration discovered that a high rate of infection of neurons in the brain with the herpes virus could be behind conditions such as bipolar disorder and severe depression.

Images via Shutterstock

Previous post

UK Biotech Raises €73M to Target DNA Repair in Treating Cancer

Next post

Culturing Bacteria in a Lifesize Human Body Sculpture

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.